Introduction
============

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Lung adenocarcinoma is the main type of NSCLC.[@b1-ott-6-497] Owing to its complex tumorigenesis, lung adenocarcinoma is exceedingly difficult to treat and prognosticate. Recently, in order to find therapeutic targets and prognostic biomarkers, research on lung adenocarcinoma has focused on gene mutations.

The activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway is thought to play a critical role in the development of lung cancer.[@b2-ott-6-497] As in most cancers, during the development of lung adenocarcinoma, genetic defects accumulate, resulting in the altered activity of the PI3K/AKT signaling pathway. The *PIK3CA* gene encodes the catalytic p110-α subunit of PI3K.[@b3-ott-6-497] It has been suggested that *PIK3CA* is somatically mutated in lung cancers.[@b4-ott-6-497] Most of the previous studies investigated the *PIK3CA* mutations using gene sequencing technology, and the positive mutation rate was less than 10% in lung cancer.[@b5-ott-6-497],[@b6-ott-6-497] Recently, the research of Chaft et al detected four types of *PIK3CA* mutations (E545K, E542K, H1047R, and H1047L) in lung adenocarcinoma; however, the rate of mutation was only 2% by mass spectrometry--based nucleic acid assay technology.[@b7-ott-6-497] It was unclear about the relation between *PIK3CA* mutations and patient prognosis. We need more research to understand the impact of *PIK3CA* mutations in lung adenocarcinoma. Therefore, we attempted to detect the frequency of *PIK3CA* mutations using a new method -- amplification refractory mutation system (ARMS) allele-specific polymerase chain reaction (PCR) -- and also assessed the clinicopathologic significance and prognosis of *PIK3CA* mutation status, in a large series of lung adenocarcinoma.[@b8-ott-6-497]

The aim of this study was to identify significantly mutated loci not previously associated with lung adenocarcinoma and to describe the relationships between *PIK3CA* mutations and clinical features. Moreover, our integration of ARMS-PCR and mutation data provides a novel view of *PIK3CA* alterations in lung adenocarcinoma. These findings further our understanding of lung adenocarcinoma and provide clues to prognosis and new therapeutic targets.

Materials and methods
=====================

Patients and tissue samples
---------------------------

The analysis was conducted in 122 patients with histologically confirmed primary lung adenocarcinoma who underwent surgical resection between April 2008 and September 2010 at the Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China. All patients gave informed consent according to a study protocol that was approved by Beijing Chest Hospital Human Tissue Committee and Research Ethics Board (REB). All tissue samples had been flash frozen in liquid nitrogen within 30 minutes of surgery and stored at −80°C. The age of the studied patients ranged from 36 to 83 years with a median of 61.5 years. The histological classification was based on the 2004 World Health Organization criteria. Tumors were staged according to the 2009 Union for International Cancer Control guidelines. The detailed clinical characteristics of the 122 primary lung adenocarcinoma patients are listed in [Table 1](#t1-ott-6-497){ref-type="table"}.

DNA extraction
--------------

The DNA was extracted from the frozen tissues using the TIANamp Genomic DNA Kit (Tiangen Biotech, Beijing, People's Republic of China), according to the manufacturer's protocol. The DNA was qualitatively assessed by agarose gel electrophoresis and was quantified spectrophotometrically, to confirm that A260/A230 value is greater than 2.0 and A260/A280 value between 1.8 and 2.0.

Detection of *PIK3CA* mutations
-------------------------------

For the ARMS-PCR analysis of the five common *PIK3CA* mutations (E542K, E545K, and E545D mutation in exon 9, H1047R and H1047L mutation in exon 20), samples were loaded, in triplicate, into 96-well reaction plates, using the AmoyDx™ *PIK3CA* Five Mutation Detection Kit (Amoy Diagnostics Co, Ltd, Xiamen, People's Republic of China), according to the manufacturer's instructions, for each sample. The mutation assay for each sample and control assay (*PIK3CA* mixed standard and no-template controls) were analyzed in the same PCR run, to avoid run-to-run variations in threshold settings. The assays were performed with the Applied Biosystems 7500 Real-Time PCR System (Life Technologies, Carlsbad, CA, USA). Predenaturing was carried out at 95°C for 5 minutes, followed by 15 cycles of denaturing at 95°C for 25 seconds, 64°C for 20 seconds, and 72°C for 20 seconds, in order to reach a full plateau for all samples, and was followed by the detection stage with 20 cycles at 93°C for 25 seconds, 60°C for 35 seconds, and 72°C for 20 seconds. The analysis of the target mutations in the samples was accomplished by measuring the fractional cycle number at which the degree of expression reached a fixed cycle threshold (C~T~). Based on different mutant C~T~ values, the detection results were categorized as either positive or negative for mutation.

Statistical analysis
--------------------

Chi-square and the Fisher's exact test were used to analyze the association of mutations with clinical characteristics. The Kaplan--Meier method was used to estimate survival and progress free survival, and the exact log rank test was used to compare differences in survival the distributions among groups. All data were analyzed by statistical software SPSS 16.0 (SPSS Inc, Chicago, IL, USA). A *P*-value less than 0.05 was considered to be statistically significant.

Results
=======

*PIK3CA* mutations were found in lung adenocarcinoma
----------------------------------------------------

Among the 122 patients who underwent curative resection of stage I to IV lung adenocarcinoma, we detected *PIK3CA* mutations in exons 9 and 20, using ARMS-PCR technology. In all, 24 patients (19.7%) harbored at least one mutation in the regions analyzed. A total of 25 point mutations were found in these 24 patients: one mutation occurred in the helical domain (E542K, exon 9), and 24 mutations were in the kinase domain (18 of these were mutations of H1047R and six were of H1047L, exon 20). One patient carried two mutations in exon 20 (H1047R and H1047L). The "hot spot" was H1047R, located in the kinase domain (exon 20). None of the patients showed mutations in both exon 9 and exon 20. The frequency and distribution of the mutations are shown in [Table 2](#t2-ott-6-497){ref-type="table"}.

*PIK3CA* mutations correlated with lymph node (Ln) status and tumor stage
-------------------------------------------------------------------------

We analyzed the clinical characteristics of the lung adenocarcinoma cases according to *PIK3CA* mutation status ([Tables 2](#t2-ott-6-497){ref-type="table"} and [3](#t3-ott-6-497){ref-type="table"}). Compared with *PIK3CA* wild-type tumors, *PIK3CA* mutations were found more frequently in tumors with LN metastasis (LN \[+\]), 20 point mutations in LN (+), and five point mutations in LN patients without LN metastasis (LN \[−\]) (*P* = 0.029). *PIK3CA* mutations occurred in 12% (6/50) of patients at early clinicopathologic stage (I--II) and in 26.4% (19/72) of patients at advanced stage (III--IV) disease, but the association was not statistically significant (*P* = 0.122). *PIK3CA* mutations were not associated with smoking status in the total group of patients (*P* = 0.78). No correlation was identified between the *PIK3CA* mutation rate and distant metastasis, age, or gender.

*PIK3CA* mutations and patient progression-free survival (PFS)
--------------------------------------------------------------

We assessed the influence of *PIK3CA* mutation on patient PFS in resectable lung adenocarcinoma. The median follow up for the cohort was 19 months (0--47 months). Patients harboring *PIK3CA*-mutated lung adenocarcinoma showed a marginally significant shorter median PFS of 12 months (0--42 months) compared with patients with *PIK3CA* wildtype tumors, for whom median PFS was about 20 months (1--47 months). The patients with *PIK3CA*-mutated tumors experienced an increase in cancer-specific mortality, although statistical significance was not reached (*P* = 0.385) ([Figure 1A](#f1-ott-6-497){ref-type="fig"}). We also assessed the five *PIK3CA* mutation types separately. In our study, the H1047R mutant is the most common mutation. H1047R mutations associated with survival, and reached statistical significance (*P* = 0.032) ([Figure 1B](#f1-ott-6-497){ref-type="fig"}); the median PFS of H1047R (+) patients was 9 months (95% confidence interval \[CI\] 7.2--10.8), far under the median PFS of 26 months (95% CI 17.2--36.8) for H1047R (−) patients.

Discussion
==========

Most of the reported *PIK3CA* mutations were localized at hotspots in exon 9 and exon 20 of the gene. Exon 20 encodes the catalytic domain of p110α, and mutations in this domain may constitutively activate its enzymatic activity. Exon 9 encodes the helical domain of p110α, and those mutations depress an inhibitory interaction between the N-terminal Src homology 2 (SH2) domain of p85 and the p110α catalytic subunit. Expression of the *PIK3CA* mutations leads to increased oncogenic potential in vitro and in vivo. Direct gene sequencing has been commonly used to analyze mutations of the *PIK3CA* gene. However, this method was unable to detect the presence of mutant *PIK3CA* when present at \<30% of the total.[@b8-ott-6-497] The ARMS-PCR assay, a new detection method, identified more mutations in the clinical samples than did direct sequencing. The ARMS--PCR assays were able to detect the presence of mutations at 1% of the total. These assays were more sensitive than sequencing and could detect five copies of mutant DNA in proportions as low as 0.1% of the total DNA.[@b8-ott-6-497] In our study, we tested the five "hotspot" mutations (E542K, E545K, E545D mutation in exon 9, H1047R and H1047L mutation in exon 20) in 122 lung adenocarcinomas using ARMS--PCR; we found that the positive rate (19.7%) was much higher than in early reports studies.[@b7-ott-6-497],[@b9-ott-6-497],[@b10-ott-6-497]

The *PIK3CA* mutations found in human cancers primarily occur at two "hot spots:" E545K in the helical domain and H1047R in the catalytic domain.[@b7-ott-6-497],[@b11-ott-6-497],[@b12-ott-6-497] These mutations are known to promote the catalytic activity of p110α, thereby leading to constitutive activation of the PI3K signaling pathway.[@b13-ott-6-497] Research by Engelman et al indicated that transgenic mice with lung-specific induction of the kinase-domain mutant p110α H1047R (in exon 20) developed lung adenocarcinoma.[@b14-ott-6-497] Yamaguchi et al determined that E545K and H1047R mutations in p110α enhanced invadopodia-mediated extracellular matrix degradation and invasion.[@b15-ott-6-497] This finding provides mechanistic insight into the role of p110α mutations in cancer invasion, and Yamaguchi suggested that PI3K signaling, via p110α, regulates invadopodia-mediated invasion and migration of breast cancer cells.[@b15-ott-6-497] In this study, we analyzed the clinicopathologic significance of five "hotspot" *PIK3CA* mutations among 122 lung adenocarcinoma patients. The data showed that *PIK3CA* mutations were associated with LN metastasis. Lung adenocarcinoma patients with LN (+) had many more mutations (20 in 70 cases, 28.6%) than did patients with LN (−) (five in 52 cases, 9.6%) (*P* = 0.029). Moreover, there was no significant association between *PIK3CA* mutations and age (*P* = 0.32), distant metastasis (*P* = 0.79), smoking status (*P* = 0.78), or clinicopathologic stage (*P* = 0.122), by Chi-square test. However, mutations were found less frequently in the early clinicopathologic stage patients (six in 50 cases, 12%) than in advanced stage (19 in 72 cases, 26.4%).

*PIK3CA* mutations activate AKT through phosphorylation, and pAKT expression has been reported to be associated with poor prognosis.[@b15-ott-6-497] Some studies have shown that *PIK3CA* mutation predicts shorter survival in colorectal and breast cancers.[@b16-ott-6-497]--[@b21-ott-6-497] Because the effect of *PIK3CA* mutations on lung adenocarcinoma patient prognosis has rarely been studied, we investigated the prognostic significance of *PIK3CA* mutations in the present study. In our research, we examined on prognostic significance of five hot spot *PIK3CA* mutations in 122 lung adenocarcinoma patients, focusing on PFS. In our study, the H1047R mutant is the most common mutation. H1047R mutations associated with survival, and reached statistical significance (*P* = 0.032) ([Figure 1B](#f1-ott-6-497){ref-type="fig"}). The median PFS of H1047R (+) patients was 9 months (95% CI 7.2--10.8), which was far under that of H1047R (−) patients, who had a mean PFS of 26 months (95% CI 17.2--36.8). In our cohorts, the data on cancer treatment were limited. Nonetheless, it is unlikely that chemotherapy use differed according to tumor *PIK3CA*-mutated status because such data were not available to patients or treating physicians.

In summary, our study suggests that *PIK3CA* mutation is associated with poor prognosis in resectable lung adenocarcinoma. This finding may have considerable clinical implications. Considerable effort has been focused on identifying therapeutic inhibitors of the PI3K/AKT pathway, in lung adenocarcinoma as well as in other common malignancies. Future studies are needed to confirm the association between *PIK3CA* mutations and the PI3K/AKT pathway and as well, to elucidate the exact mechanisms by which *PIK3CA* mutations affect tumor behavior. Thus, advances in the understanding of the molecular mechanisms of lung adenocarcinoma will lead to the development of novel and individualized anticancer therapeutic strategies.
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![Kaplan--Meier curves for PFS in lung adenocarcinoma with five *PIK3CA* mutations (**A**) and for the H1047R mutation type (**B**).\
**Notes:** In (**A**), lung adenocarcinoma patients harboring *PIK3CA* with mutation (n = 20) showed a marginally significant shorter median PFS of 12 months (0--42 months) compared with 20 months (1--47 months) in patients without mutation (n = 92). The patients with *PIK3CA*-mutated tumors experienced an increase in cancer-specific mortality, although statistical significance was not reached (*P* = 0.385). In (**B**), the median PFS of H1047R mutation-positive patients (n = 16) was 9 months (95% CI 7.2--10.8), far under the median PFS of 26 months (95% CI 17.2--36.8) for H1047R mutation-negative patients (n = 96). H1047R mutations associated with survival, and reached statistical significance (*P* = 0.032). When the mutation of H1047R was included, the association reached statistical significance (*P* = 0.032).\
**Abbreviations:** CI, confidence interval; cum, cumulative; PFS, progression-free survival.](ott-6-497Fig1){#f1-ott-6-497}

###### 

Clinical characteristics of 122 patients

                            Total   Sex   *P*   
  ------------------------- ------- ----- ----- ------------------------------------------------
  Number of patients        122     72    50    
  Age (years)                                   
   0--60                    60      31    29    0.10
   \>60                     62      41    21    
  Lymph node status                             
   Ln (−)                   50      34    18    0.22
   Ln (+)                   72      38    32    
  Distant metastasis                            
   M (−)                    111     64    47    0.52
   M (+)                    11      8     3     
  Clinicopathologic stage                       
   I--II                    50      30    20    0.85
   III--IV                  72      42    30    
  Smoking status                                
   Smoker                   59      55    4     0.000[a](#tfn1-ott-6-497){ref-type="table-fn"}
   Nonsmoker                60      16    44    
   Missing                  3       1     2     

**Note:**

Smoking status is significantly associated with gender.

**Abbreviations:** Ln, lymph node; M, metastasis.

###### 

Frequency of each *PIK3CA* mutation type in lung adenocarcinoma

  Exon                      Total (%)                                             Exon 20     Exon 9                                                      
  ------------------------- ----------------------------------------------------- ----------- ---------- ---------- ---------- --- --- --- ---------- --- ---
  Number of mutations       25 (20.5%)[a](#tfn3-ott-6-497){ref-type="table-fn"}   10 (8.2%)   8 (6.6%)   3 (2.5%)   3 (2.5%)   0   0   0   1 (0.8%)   0   0
  Age (years)                                                                                                                  0   0   0   1 (0.8%)   0   0
   0--60                    15 (12.3%)                                            5 (4.1%)    6 (4.9%)   3 (2.5%)   0          0   0   0   0          0   0
   \>60                     10 (8.2%)                                             5 (4.1%)    2 (1.6%)   0          3 (2.5%)   0   0   0   0          0   0
  Lymph node status                                                                                                                                       
   Ln (−)                   5 (4.1%)                                              1 (0.8%)    3 (2.5%)   1 (0.8%)   0          0   0   0   0          0   0
   Ln (+)                   20 (16.4%)[b](#tfn4-ott-6-497){ref-type="table-fn"}   9 (7.4%)    5 (4.1%)   2 (1.6%)   3 (2.5%)   0   0   0   1 (0.8%)   0   0
  Distant metastasis                                                                                                                                      
   M (−)                    22 (18%)                                              9 (7.4%)    7 (5.7%)   2 (1.6%)   3 (2.5%)   0   0   0   1 (0.8%)   0   0
   M (+)                    3 (2.5%)                                              1 (0.8%)    1 (0.8%)   1 (0.8%)   0          0   0   0   0          0   0
  Clinicopathologic stage                                                                                                                                 
   I--II                    6 (4.9%)                                              2 (1.6%)    3 (2.5%)   1 (0.8%)   0          0   0   0   0          0   0
   III--IV                  19 (15.6%)                                            8 (6.6%)    5 (4.1%)   2 (1.6%)   3 (2.5%)   0   0   0   1 (0.8%)   0   0
  Smoking status                                                                                                                                          
   Smoker                   13 (10.7%)                                            9 (7.4%)    0          3 (2.5%)   1 (0.8%)   0   0   0   0          0   0
   Nonsmoker                11 (9.0%)                                             0           8 (6.6%)   0          2 (1.6%)   0   0   0   1 (0.8%)   0   0
   Missing                  1 (0.8%)                                              1 (0.8%)    0          0          0          0   0   0   0          0   0

**Notes:**

One sample had both mutations of H1047R and H1047L;

*P* \< 0.05.

**Abbreviations:** LN, lymph node; M, metastasis.

###### 

Clinical characteristics according to *PIK3CA* mutation status in lung adenocarcinoma

                            Total (n = 122) N (%)   *PIK3CA* mutation status   *P*[a](#tfn7-ott-6-497){ref-type="table-fn"}   
  ------------------------- ----------------------- -------------------------- ---------------------------------------------- ------------------------------------------------
  Age (years)                                                                                                                 
   Mean (range)             60 (36--83)             61 (37--83)                58 (36--73)                                    
   0--60                    60 (49%)                46 (47%)                   14 (58%)                                       0.32
   \>60                     62 (51%)                52 (53%)                   10 (42%)                                       
  Lymph node status                                                                                                           
   Ln (−)                   52 (43%)                47 (48%)                   5 (21%)                                        0.029[b](#tfn7-ott-6-497){ref-type="table-fn"}
   Ln (+)                   70 (57%)                51 (52%)                   19 (79%)                                       
  Distant metastasis                                                                                                          
   M (−)                    111 (91%)               89 (91%)                   22 (92%)                                       0.79
   M (+)                    11 (9%)                 9 (9%)                     2 (8%)                                         
  Clinicopathologic stage                                                                                                     
   I--II                    50 (41%)                44 (45%)                   6 (25%)                                        0.122
   III--IV                  72 (59%)                54 (55%)                   18 (75%)                                       
  Smoking status                                                                                                              
   Smoker                   59 (48%)                47 (48%)                   12 (50%)                                       0.78
   Nonsmoker                60 (49%)                49 (50%)                   11 (46%)                                       
   Missing                  3 (2%)                  2 (2%)                     1 (4%)                                         

**Notes:**

χ^2^ test used for binary/categorical variables;

*P* \< 0.05.

**Abbreviations:** Ln, lymph node; M, metastasis.

[^1]: \*These authors contributed equally to this work
